PreciDIAB

Our members

DietSensor, makers of the CES Las Vegas award-winning dietary rebalancing app of the same name, is on a mission to help anyone with a chronic disease, starting with diabetes, use knowledge scientifically validated on balanced diet as a lever of action with high impact for the management of one’s disease. The platform’s educational content, advice, menus and innovative tools have been broken down into two mobile applications: DietSensor to help prevent overweight and Diet&You, to empower patients in optimizing their food choices. Diet&You takes into account multiple cross-pathologies such as Diabetes, dislipidemia and hypertension. It also makes it possible to eat better and to avoid undernutrition during episodes of treatment against cancer.

Rémy Bonnasse, CEO and co-founder of DietSensor :

Joining PreciDIAB gives us the opportunity to collaborate with public and private institutional partners to set up programs that support patient therapies through learning to eat a balanced diet independently.

 

AstraZeneca is a science-driven international biopharmaceutical company focused on research, development and commercialization of prescription drugs, primarily for the treatment of diseases in three major therapeutic areas: Oncology, Cardiovascular, Kidney and Metabolic ( CVRM), and Respiratory diseases & Immunology

Richard Carayan, Regional Medical Manager :

Membership of the PreciDIAB club was motivated by the idea of joining a group of researchers and opinion leaders in an area in which, with our iSGLT2, we hope to contribute to the advancement of knowledge. We are also particularly interested in patient cohorts in renal cardiovascular and metabolic pathologies.

Bayer is an international Life Sciences group, whose core businesses are health and agriculture. Bayer’s products and services are designed to meet the challenges of a growing and aging global population, protecting everyone every day. Creating value through innovation and science, Bayer is strongly committed to sustainable development and adopts transparent and responsible conduct in its activities. In 2020, Bayer had nearly 100,000 employees and generated sales of 41.4 billion euros. The Group spent 4.9 billion euros on R&D.

Bayer’s Pharmaceuticals Division provides healthcare professionals and patients with prescription drugs for the therapeutic areas of cardiology, oncology, women’s health, hematology and ophthalmology as well as radiology. By enabling the diagnosis and treatment of diseases, as well as the development of digital solutions to optimize the patient’s care path, Bayer is working for greater well-being and an improvement in the quality of life of patients. Mouna Champain, Medical Director France :
Bayer, as a recognized player in the care of patients with cardiovascular pathologies, aims to contribute more widely to improving the care of patients at risk of developing complications, particularly in the context of of their diabetes. The PreciDIAB Initiative fits perfectly into the positioning we must have to support the molecules in our pipeline through large-scale partnerships!

COLORE MA VIE has developed an innovative gamified design method to co-design solutions by and for chronic patients. Founded by an engineer and a designer, COLORE MA VIE thus offers the design of accessories for carrying and transporting care devices, edutainment support intended for therapeutic patient education and consulting services in the gamification of care pathways. care or digital health applications.

Aline Chemineau, co-founder :

Joining PreciDIAB will give COLORE MA VIE the opportunity to exchange with many industrial and academic partners and thus enrich our practice. The clinical research aspect is also an area that COLORE MA VIE wishes to deepen.

Defymed is a company developing innovative implantable medical devices. ExOlin® allows the intraperitoneal delivery of insulin by being coupled to an external insulin pump (start of clinical trials expected by the end of 2020). MailPan® is a device for the macro-encapsulation of insulin-secreting cells. Our goal is to find the best device / cell combination in order to hope for the start of clinical trials in 2022.

Dr Manuel PIRES , Defymed Business Developer :

PreciDIAB is a unique opportunity for Defymed to join a network of opinion leaders in the field of diabetes. Through PreciDIAB, Defymed will participate in workshops and strategic discussions with potential partners.

Diabeloop is revolutionizing healthcare innovation with self-learning and interoperable solutions for diabetes management. Our mission: to make innovation accessible to people with diabetes: to improve clinical results while relieving them of their constant mental load.

Diabeloop :

Joining PreciDIAB is an excellent opportunity for Diabeloop to be able to exchange with major academic or industrial players in the field of diabetes. This membership will allow us to support us in the development of new innovative solutions.

DiappyMed is a publisher of mobile solutions specializing in the field of diabetes. Our mission is to improve the care of diabetic patients by making personalized insulin treatment accessible to everyone. We are developing an app that can potentiate insulin treatment and offer more freedom and autonomy to patients.

Coralie Lefevre, co-founder and director of development: :

PreciDIAB is for DiappyMed a valuable opportunity to get closer to opinion leaders in the field of diabetes in order to understand unmet medical needs and expectations in terms of clinical evaluation of digital therapies.

DietSensor, makers of the CES Las Vegas award-winning dietary rebalancing app of the same name, is on a mission to help anyone with a chronic disease, starting with diabetes, use knowledge scientifically validated on balanced diet as a lever of action with high impact for the management of one’s disease. The platform’s educational content, advice, menus and innovative tools have been broken down into two mobile applications: DietSensor to help prevent overweight and Diet&You, to empower patients in optimizing their food choices. Diet&You takes into account multiple cross-pathologies such as Diabetes, dislipidemia and hypertension. It also makes it possible to eat better and to avoid undernutrition during episodes of treatment against cancer.

Rémy Bonnasse, CEO and co-founder of DietSensor :

Joining PreciDIAB gives us the opportunity to collaborate with public and private institutional partners to set up programs that support patient therapies through learning to eat a balanced diet independently.

Enterome is a world leader in the discovery and development of new pharmaceuticals derived from the gut microbiota in the fields of cancer, autoimmune, inflammatory and metabolic diseases.

Christophe BONNY , Chief Scientific Officer d’Enterome :

Joining the PreciDIAB initiative Club allows us to integrate the expertise of opinion leaders in metabolic diseases and in particular in the field of Diabetes, to have access to the results of translational studies of cohorts of patients in these pathologies and to have the opportunity to propose and participate in collaborative projects.

GDBiotech is a spin-off of the Genes Diffusion group which hosts a portfolio of technologies and patents finding applications in fields as varied as molecular diagnostic (qPCR) and immunological (multiplex ELISA) solutions, bioinformatics tools for the automation of DNA sequence analyzes, and the study of the microbiota.

Claude Grenier, CEO of GD Biotech :

Our company has no direct link with human health research. However, we have developed or applied for our activity many technological and even scientific methods similar to those applicable in human health research. We would like to share with the members of this network around these favorite subjects.

Novo Nordisk is an international pharmaceutical company headquartered in Copenhagen, Denmark. We specialize in the treatment of diabetes and other serious chronic diseases such as obesity, rare bleeding diseases and growth disorders.

We employ more than 45,000 people in 80 subsidiaries around the world. Our healthcare solutions are available in 169 countries.

Jean-Paul Roudière, Director of Hospital Relations :

Joining the PreciDIAB initiative club means participating in excellent research on diabetes, but also collaborating with public and private institutional partners in prevention and health promotion programs.

RNPC is the first private national network for the management of overweight in collaboration with doctors.

In our centers, we take care of people who are overweight, obese and who often have comorbidities (HTA, DT2, metabolic syndrole, metabolic steatohepatitis, OSAS, etc.)

We offer these patients at high cardiometabolic risk a therapeutic weight loss goal.

All national and international recommendations recommend a significant weight loss (10-15%) in order to improve or even cure these pathologies.

The RNPC program is an individualized nutritional rehabilitation program that provides rapid, consistent weight loss followed by lasting weight stabilization.

The rationale for the RNPC program is entirely based on solid scientific evidence, and in particular on the clinical protocol and the results of the DIOGENES study, namely:

  • a slimming phase during which food intake is restricted and optimally distributed between macronutrients in order to obtain rapid results, without hunger or fatigue, which contributes to a much better observance, adherence to the program
  • a stabilization phase specifically established for each patient allowing him to return to a balanced diet.
  • a phase of balance

Each patient is sent to us at the center by their doctor and is followed every 15 days by a dietitian during the entire program (i.e. for 8-10 months on average).

Xavier Marion, Director :

At RNPC, we have the ambition to become essential partners of doctors confronted in their daily lives with overweight and the comorbidities that are often associated with it.

My objective, by joining the network, is to publicize the RNPC program and its effectiveness, but also to contribute to collaborative projects aimed at improving the care of patients at risk of developing complications due to their weight.

I remain convinced that by working in a network, we can truly optimize our care.

StarkAge Therapeutics is a privately-held, early-stage biotechnology company and pioneer in the field of senescence. Based in France in Lille, it was founded in 2018 by Dr. Thierry Mathieu on the idea that the elimination by targeted immunotherapy of senescent cells specific to certain age-related diseases could bring significant therapeutic benefits to patients. Initially, we focus on pulmonary fibrosis and hepatic fibrosis (NASH/NAFLD)

Pierre-Michel Bringer – CEO StarkAge Therapeutics :

Joining the PreciDIAB club was obvious for a young start-up like ours. Being able to discuss with academic and industrial experts, and share our experiences and knowledge, is a major source of mutual enrichment.

Valbiotis is a Research & Development company committed to scientific innovation, for the prevention and the fight against metabolic diseases in response to unmet medical needs.

Sébastien Peltier, CEO of Valbiotis :

The PreciDIAB club brings together a national network of academic and industrial partners who have skills and expertise in the field of diabetes, it is obvious for Valbiotis to join it and to contribute to scientific excellence.